Transcriptome Analysis Identifies ALCAM Overexpression As a Prognosis Biomarker in Laryngeal Squamous Cell Carcinoma

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2020 Feb 23

PMID 32085563

Citations 11

Authors

Pedro Nicolau-Neto

Paulo Thiago de Souza-Santos

Mariana Severo Ramundo

Priscila Valverde

Ivanir Martins

Izabella Costa Santos

Fernando Dias

Tatiana de Almeida Simao

Luis Felipe Ribeiro Pinto

Affiliations

Soon will be listed here.

Abstract

Background: Laryngeal squamous cell carcinoma (LSCC) is one of the most incident tumors in the world, especially in developing countries, such as Brazil. Different from other tumors, LSCC prognosis did not improve during the past four decades. Therefore, the objective of this study was to develop biomarkers that can predict LSCC patient's prognosis.

Results: Transcriptome analysis pointed out 287 overexpressed genes in LSCC in comparison to adjacent mucosa. Among these, a gene-pattern signature was created with 24 genes associated with prognosis. The Bayesian clustering of both Brazil and The Cancer Genome Atlas (TCGA) data pointed out clusters of samples possessing significative differences in the prognosis, and the expression panel of three genes (, , and ) was capable to distinguish patients with worse prognosis with an accuracy of 97%. Survival analyses with TCGA data highlighted gene expression as an independent prognostic factor for LSCC. This was further confirmed through immunohistochemistry, using a validation set of Brazilian patients. A expression was not associated with prognosis for other head and neck tumor sites.

Conclusion: ALCAM overexpression seems to be an independent prognosis biomarker for LSCC patients.

Citing Articles

Significance of Malic Enzyme 1 in Cancer: A Review.

Fujiwara-Tani R, Nakashima C, Ohmori H, Fujii K, Luo Y, Sasaki T Curr Issues Mol Biol. 2025; 47(2).

PMID: 39996805 PMC: 11854147. DOI: 10.3390/cimb47020083.

IncRNA AC004943.2 regulates miR-135a-5p and PTK2/P13K axis to promote laryngeal squamous cell carcinoma progression.

Zhu X, Dong W, Zhang M J Cell Commun Signal. 2024; 18(1):e12016.

PMID: 38545258 PMC: 10964940. DOI: 10.1002/ccs3.12016.

Overexpression of malic enzyme is involved in breast cancer growth and is correlated with poor prognosis.

Hu W, Yang Y, Cheng C, Tu Y, Chang H, Tsai K J Cell Mol Med. 2024; 28(6):e18163.

PMID: 38445776 PMC: 10915829. DOI: 10.1111/jcmm.18163.

IGF2BP2 acts as a mA modification regulator in laryngeal squamous cell carcinoma through facilitating CDK6 mRNA stabilization.

Tang X, Tang Q, Li S, Li M, Yang T Cell Death Discov. 2023; 9(1):371.

PMID: 37816718 PMC: 10564923. DOI: 10.1038/s41420-023-01669-7.

Identification of an immune-related genes signature to predict risk of recurrence for patients with laryngeal squamous cell carcinoma.

Hong X, Li Y, Lv Q, An J, Liu Y, Wang X Int J Immunopathol Pharmacol. 2023; 37:3946320231172075.

PMID: 37073715 PMC: 10127216. DOI: 10.1177/03946320231172075.

References

Zhou S, Piao X, Wang C, Wang R, Song Z . Identification of claudin‑1, ‑3, ‑7 and ‑8 as prognostic markers in human laryngeal carcinoma. Mol Med Rep. 2019; 20(1):393-400. PMC: 6580001. DOI: 10.3892/mmr.2019.10265. View

Linnekamp J, van Hooff S, Prasetyanti P, Kandimalla R, Buikhuisen J, Fessler E . Consensus molecular subtypes of colorectal cancer are recapitulated in in vitro and in vivo models. Cell Death Differ. 2018; 25(3):616-633. PMC: 5864202. DOI: 10.1038/s41418-017-0011-5. View

Mermel C, Schumacher S, Hill B, Meyerson M, Beroukhim R, Getz G . GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011; 12(4):R41. PMC: 3218867. DOI: 10.1186/gb-2011-12-4-r41. View

Ibanez A, Sarrias M, Farnos M, Gimferrer I, Serra-Pages C, Vives J . Mitogen-activated protein kinase pathway activation by the CD6 lymphocyte surface receptor. J Immunol. 2006; 177(2):1152-9. DOI: 10.4049/jimmunol.177.2.1152. View

Santos R, Oliveira L, Carmo A . Tuning T Cell Activation: The Function of CD6 At the Immunological Synapse and in T Cell Responses. Curr Drug Targets. 2015; 17(6):630-9. DOI: 10.2174/1389450116666150531152439. View

Wettenhall J, Smyth G . limmaGUI: a graphical user interface for linear modeling of microarray data. Bioinformatics. 2004; 20(18):3705-6. DOI: 10.1093/bioinformatics/bth449. View

Bai Z, Shi E, Wang Q, Dong Z, Xu P . A potential panel of two-long non-coding RNA signature to predict recurrence of patients with laryngeal cancer. Oncotarget. 2017; 8(41):69641-69650. PMC: 5642505. DOI: 10.18632/oncotarget.18751. View

Masedunskas A, King J, Tan F, Cochran R, Stevens T, Sviridov D . Activated leukocyte cell adhesion molecule is a component of the endothelial junction involved in transendothelial monocyte migration. FEBS Lett. 2006; 580(11):2637-45. DOI: 10.1016/j.febslet.2006.04.013. View

Zimmerman A, Joosten B, Torensma R, Parnes J, van Leeuwen F, Figdor C . Long-term engagement of CD6 and ALCAM is essential for T-cell proliferation induced by dendritic cells. Blood. 2005; 107(8):3212-20. DOI: 10.1182/blood-2005-09-3881. View

10.

Li C, Wong W . Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc Natl Acad Sci U S A. 2001; 98(1):31-6. PMC: 14539. DOI: 10.1073/pnas.98.1.31. View

11.

Larque A, Conde L, Hakim S, Alos L, Jares P, Vilaseca I . P16(INK⁴a) overexpression is associated with CDKN2A mutation and worse prognosis in HPV-negative laryngeal squamous cell carcinomas. Virchows Arch. 2015; 466(4):375-82. DOI: 10.1007/s00428-015-1725-8. View

12.

Swart G, Lunter P, van Kilsdonk J, van Kempen L . Activated leukocyte cell adhesion molecule (ALCAM/CD166): signaling at the divide of melanoma cell clustering and cell migration?. Cancer Metastasis Rev. 2005; 24(2):223-36. DOI: 10.1007/s10555-005-1573-0. View

13.

Jeong Y, Oh H, Park S, Bong J . Prognostic Significance of Activated Leukocyte Cell Adhesion Molecule (ALCAM) in Association with Promoter Methylation of the ALCAM Gene in Breast Cancer. Molecules. 2018; 23(1). PMC: 6017653. DOI: 10.3390/molecules23010131. View

14.

Ben-Dayan M, Ow T, Belbin T, Wetzler J, Smith R, Childs G . Nonpromoter methylation of the CDKN2A gene with active transcription is associated with improved locoregional control in laryngeal squamous cell carcinoma. Cancer Med. 2017; 6(2):397-407. PMC: 5313649. DOI: 10.1002/cam4.961. View

15.

Logothetis C, Gallick G, Maity S, Kim J, Aparicio A, Efstathiou E . Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer. Cancer Discov. 2013; 3(8):849-61. PMC: 3926428. DOI: 10.1158/2159-8290.CD-12-0460. View

16.

. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015; 517(7536):576-82. PMC: 4311405. DOI: 10.1038/nature14129. View

17.

Xiao M, Yan M, Zhang J, Xu Q, Qi S, Wang X . Cancer stem-like cell related protein CD166 degrades through E3 ubiquitin ligase CHIP in head and neck cancer. Exp Cell Res. 2017; 353(1):46-53. PMC: 5381905. DOI: 10.1016/j.yexcr.2017.03.005. View

18.

Andisheh-Tadbir A, Ashraf M, Khademi B, Ahmadi S . Clinical implication of CD166 expression in salivary gland tumor. Tumour Biol. 2014; 36(4):2793-9. DOI: 10.1007/s13277-014-2905-x. View

19.

Clauditz T, von Rheinbaben K, Lebok P, Minner S, Tachezy M, Borgmann K . Activated leukocyte cell adhesion molecule (ALCAM/CD166) expression in head and neck squamous cell carcinoma (HNSSC). Pathol Res Pract. 2014; 210(10):649-55. DOI: 10.1016/j.prp.2014.06.012. View

20.

Swart G . Activated leukocyte cell adhesion molecule (CD166/ALCAM): developmental and mechanistic aspects of cell clustering and cell migration. Eur J Cell Biol. 2002; 81(6):313-21. DOI: 10.1078/0171-9335-00256. View